El Lilly’s (LLY) blockbuster weight-loss drug Zepbound is now eligible for Medicare coverage. The news could significantly ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

Eli Lilly’s obesity drug Zepbound is now covered by Medicare for sleep apnea treatment, expanding access to the costly ...

In a recent episode of the global health and wellness show Bloom, host Gayle Guyardo welcomed Dr. Bharti Shetye, MD, MFOMA, a ...

Eli Lilly's (NYSE:LLY) weight-loss drug Zepbound is now reportedly covered by Medicare for the treatment of obstructive sleep ...

The Centers for Medicare & Medicaid Services confirmed to CNBC that Medicare drug plans can now cover Eli Lilly’s (LLY) obesity drug Zepbound for obstructive sleep apnea, reported Annika Kim ...

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...

"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated ...